Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_assertion type Assertion NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_head.
- NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_assertion description "[Collectively, the data suggest that the human mAb 1F5, which has recently entered clinical development under the name CDX-1127, may provide direct antitumor activity against CD27-expressing lymphoma or leukemia, independent of its potential to enhance immunity through its agonistic properties.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_provenance.
- NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_assertion evidence source_evidence_literature NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_provenance.
- NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_assertion SIO_000772 22589397 NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_provenance.
- NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_assertion wasDerivedFrom befree-20140225 NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_provenance.
- NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_assertion wasGeneratedBy ECO_0000203 NP515730.RAclK3PKWe300qY9AnGnOd3mkLlX7FichsBEVY93uJX0U130_provenance.